Cargando…

Regional variation of the off-licence use of rFVIIa for patients with uncontrolled haemorrhage in England

Detalles Bibliográficos
Autores principales:	Spivey, MH, Eve, RL, Duffy, MR
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2934540/ http://dx.doi.org/10.1186/cc8603

Ejemplares similares

Analysis of the off-licence use of recombinant activated factor VII for patients with uncontrolled haemorrhage in a UK tertiary referral hospital
por: Spivey, M, et al.
Publicado: (2009)

Analysis of red cell transfusion practices in patients without active haemorrhage over a 12-month period in a UK intensive care unit
por: Eve, RL, et al.
Publicado: (2010)

Efficacy of recombinant activated factor VII (rFVIIa; NovoSeven(®)) in obstetrical haemorrhagic shock
por: Sobieszczyk, S, et al.
Publicado: (2003)

Bioengineering of rFVIIa Biopharmaceutical and Structure Characterization for Biosimilarity Assessment
por: Montacir, Othman, et al.
Publicado: (2018)

Nebulised recombinant activated factor VII (rFVIIa) does not attenuate the haemorrhagic effects of blast lung injury
por: Smith, Jason E, et al.
Publicado: (2019)

Recombinant activated factor VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven-year single-centre experience
por: Shah, Nurfatin Mohd, et al.
Publicado: (2018)

Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage
por: Aggarwal, Anita, et al.
Publicado: (2004)

Efficacy of activated recombinant factor VII (rFVIIa; NovoSeven(®)) in cirrhotic patients with upper gastrointestinal bleeding: a randomised placebo-controlled double-blind multicenter trial
por: Thabut, D, et al.
Publicado: (2004)

Recombinant Activated Factor VII (rFVIIa) in the Management of Major Obstetric Haemorrhage: A Case Series and a Proposed Guideline for Use
por: Bomken, Charlotte, et al.
Publicado: (2009)

Neonatal thrombocytopenia: Thrombin generation in presence of reduced platelet counts and effects of rFVIIa in cord blood
por: Haidl, Harald, et al.
Publicado: (2019)

A randomised, placebo-controlled, double-blind study to investigate the efficacy and safety of rFVIIa as adjunctive therapy for control of bleeding in patients with severe blunt trauma: a re-analysis following the exclusion of early (< 48 hours) deaths
por: Rossaint, R, et al.
Publicado: (2005)

Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients
por: Ng, Heng Joo, et al.
Publicado: (2006)

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
por: Linari, Silvia, et al.
Publicado: (2020)

Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann’s thrombasthenia
por: Poon, Man-Chiu
Publicado: (2007)

Recombinant activated factor VII (rFVIIa-NovoSeven(®)-NovoNordisk) treatment of bleeding complications in intensive care unit
por: Bonadona, A, et al.
Publicado: (2002)

Use of low dose of rFVIIa (recombinant Factor VII activated) to control late bleeding after percutaneous dilational tracheostomy
por: Nicosia, Dario, et al.
Publicado: (2019)

Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses
por: Kjalke, Marianne, et al.
Publicado: (2021)

Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) – a review of a new treatment paradigm
por: Heslet, Lars, et al.
Publicado: (2012)

Use of recombinant factor VIIa (rFVIIa) as pre-hospital treatment in a swine model of fluid percussion traumatic brain injury
por: Kim, Bobby, et al.
Publicado: (2014)

Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors
por: Milošević, Danko, et al.
Publicado: (2014)

Treatment of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus Patient With Local Pulmonary Administration of Factor VIIa (rFVIIa): A Case Report
por: Alabed, Iehab B.
Publicado: (2014)

Life-threatening bleeding in a patient with pemphigoid-induced acquired hemophilia A and successfully treated with rituximab and rFVIIa: A case report
por: Ma, Hongbing, et al.
Publicado: (2021)

Promoting hand hygiene in intensive care: “PCI Licence”
por: Joubert, D, et al.
Publicado: (2015)

Recombinant activated coagulation factor VII (rFVIIa) as an adjunctive hemostatic therapy in patients with multiple system organ failure and acute upper gastrointestinal bleeding
por: Milanov, S, et al.
Publicado: (2003)

Thromboelastometry as an Ancillary Tool for Evaluation of Coagulation Status after rFVIIa Therapy in a Pregnant Woman with Severe Hypoproconvertinemia—A Case Series and Review of the Literature
por: Krzyżanowski, Arkadiusz, et al.
Publicado: (2022)

A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost–utility analysis
por: Saiyarsarai, Parisa, et al.
Publicado: (2021)

Delayed ICU discharges and medical follow-up: a cause of increased mortality?
por: Whitaker, M, et al.
Publicado: (2015)

Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)
por: Rajpurkar, Madhvi, et al.
Publicado: (2019)

Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial
por: Kluger, Yoram, et al.
Publicado: (2007)

Case report: Intraoperative thrombosis cardiac arrest in extended right hepatectomy involving use of local haemostatic agent in intraoperative cell salvage (ICS) and administration of recombinant activated factor VII (rFVIIa)
por: Kyang, Lee S., et al.
Publicado: (2019)

Transcranial Doppler pulsatility index is a poor predictor of hydrocephalus in patients with aneurysmal subarachnoid haemorrhage
por: Kiel, MH, et al.
Publicado: (2012)

Haemodynamic effects of a fluid challenge with hydroxylethyl starch 130/0.4 (Voluven(®)) in patients suffering from symptomatic vasospasm after subarachnoid haemorrhage
por: Van Tulder, L, et al.
Publicado: (2008)

Traumatic subarachnoid haemorrhage in the ICU
por: Pérez, M González, et al.
Publicado: (2006)

Outcomes from subarachnoid haemorrhage
por: Whitehead, I, et al.
Publicado: (2009)

Impact of different haemodynamic resuscitation strategies on brain perfusion and tissue oedema markers in a model of severe haemorrhagic shock
por: Ida, KK, et al.
Publicado: (2013)

Covering the cardiac ICU at night: a national survey of existing levels of cover and the potential for change with implementation of the European working time directive
por: Eve, RL, et al.
Publicado: (2009)

Ventricular lavage for post-haemorrhagic hydrocephalus
por: Pople, Ian, et al.
Publicado: (2010)

Massive blood transfusion for obstetric haemorrhage
por: Simmons, S, et al.
Publicado: (2013)

Testing the impact of local alcohol licencing policies on reported crime rates in England
por: De Vocht, F, et al.
Publicado: (2017)

Role of thromboelastography in the management of haemorrhage: an observational analysis
por: Ward, C, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ci9qg7btjcnhr9fgtkbhemugle